Rat study finds mixed behavioral and biological effects of WIN under chronic…

Cannabinoid Receptor Agonism with WIN 55,212-2 Differentially Reshapes Behavioral and Neurobiological Responses to Chronic Unpredictable Stress.

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology • • Highly Relevant
🤖

AI Summary

This animal study asked whether activating cannabinoid receptors changes the effects of chronic stress across behavior and biological measures. Researchers assigned 32 male rats to control, stress, WIN 55,212-2, or combined stress-and-WIN groups. Stress lasted 35 days, while the cannabinoid receptor agonist WIN 55,212-2 was given during the final 21 days. The study assessed stress-related behaviors, hormone levels, brain redox markers, and gene activity.

Compared with untreated stressed rats, those given WIN showed less anhedonia-like and anxiety-like behavior, improved stress-coping responses, and lower stress-hormone elevations. Some measured gene-expression changes also improved, while others—including those involving NMDA receptors, TrkB, and SLC1A2—did not differ significantly from the stress group. Overall, responses varied by behavioral or biological measure rather than showing a uniform reversal of stress effects. This is an animal study; this abstract-based summary cannot establish effects in people or clinical benefit.

💡 Key Findings

1
In male rats exposed to chronic unpredictable stress, WIN 55,212-2 attenuated anhedonia-like and anxiety-like behaviors and improved stress-coping responses compared with untreated stressed animals.
Moderate
50%
2
WIN 55,212-2 reduced elevations in ACTH and corticosterone associated with chronic stress.
Moderate
50%
3
Expression of BDNF, CREB, 5-HT1B, and PSD-95 mRNA improved relative to untreated stressed rats, but NMDA receptor, TrkB, and SLC1A2 expression did not differ significantly.
Moderate
50%
4
The responses were domain- and marker-dependent, so the findings do not show that cannabinoid receptor activation uniformly reverses chronic-stress effects.
Good
60%

📄 Original Abstract

Chronic stress disrupts behavioral, neuroendocrine, redox, and molecular processes, but whether cannabinoid receptor activation modifies these domains uniformly remains unclear. We investigated the effects of the non-selective cannabinoid receptor agonist WIN 55,212-2 in chronic unpredictable mild stress (CUMS). Thirty-two male Wistar rats were assigned to control, CUMS, WIN, and CUMS + WIN groups. CUMS lasted 35 days; WIN 55,212-2 (0.5 mg/kg/day, i.p.) was administered during the final 21 days. Behavioral assessments were combined with circulating adrenocorticotropic hormone (ACTH) and corticosterone (CORT) measurements, brain redox markers, and mRNA expression analyses of neurotransmission, synaptic organization, and neuroplasticity markers. CUMS induced behavioral disturbances, hypothalamic-pituitary-adrenal (HPA) axis hyperactivity, redox imbalance, and altered transcript expression. WIN 55,212-2 attenuated anhedonia-like and anxiety-like behaviors, improved stress-coping responses, reduced ACTH and CORT elevations, and differentially modified redox alterations. BDNF, CREB, 5-HT1B, and PSD-95 mRNA expression significantly improved relative to untreated CUMS animals, whereas NMDA receptor, TrkB, and SLC1A2 expression did not differ significantly. These findings suggest that cannabinoid receptor agonism produces domain- and marker-dependent responses rather than uniformly reversing chronic stress-induced alterations, highlighting differential behavioral and neurobiological effects under chronic stress.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.